Potential biomarker of metformin action

Journal of Endocrinology

Volumn 221, Issue 3, 2014, Pages 363-369

  He, Ling ^a   Meng, Shumei ^a   Germain Lee, Emily L ^a,b   Radovick, Sally ^a   Wondisford, Fredric E ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KENNEDY KRIEGER INSTITUTE   (United States)

Author keywords

Diabetes; Glucose metabolism; Liver; Metabolism

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; GLUCOSE; METFORMIN;

ADOLESCENT; ADULT; ANIMAL CELL; ANTIDIABETIC ACTIVITY; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DIET RESTRICTION; FEMALE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; HUMAN; LEUKOCYTE; LIVER; LIVER CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; WILD TYPE;

DIABETES; GLUCOSE METABOLISM; LIVER; METABOLISM;

ADOLESCENT; ADULT; ANIMALS; BIOLOGICAL MARKERS; CELLS, CULTURED; CREB-BINDING PROTEIN; FASTING; FEMALE; GLUCONEOGENESIS; GLUCOSE; HEPATOCYTES; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOBLOTTING; LEUKOCYTES; LIVER; METFORMIN; MICE; MUTATION; OBESITY; PHOSPHORYLATION; SERINE;

EID: 84901620396     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1530/JOE-14-0084     Document Type: Article

References (22)

1. Aguilar D, Chan W, Bozkurt B, Ramasubbu K & Deswal A 2011 Metformin use and mortality in ambulatory patients with diabetes and heart failure. Circulation. Heart Failure 4 53-58. (doi:10.1161/CIRCHEARTFAILURE. 110.952556)
2. Bailey CJ & Day C 1989 Traditional plant medicines as treatments for diabetes. Diabetes Care 12 553-564. (doi:10.2337/diacare.12.8.553)
3. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR & Morris AD 2005 Metformin and reduced risk of cancer in diabetic patients. BMJ 330 1304-1305. (doi:10.1136/bmj.38415.708634.F7)
4. Goodman RH & Smolik S 2000 CBP/p300 in cell growth, transformation, and development. Genes and Development 14 1553-1577. (doi:10.1101/gad.14.13.1553)
5. Gundewar S, Calvert JW, Jha S, Toedt-Pingel I, Ji SY, Nunez D, Ramachandran A, Anaya-CisnerosM, Tian R & Lefer DJ 2009 Activation of amp-activated protein kinase bymetformin improves left ventricular function and survival in heart failure. Circulation Research 104 403-411. (doi:10.1161/CIRCRESAHA.108.190918)
6. Guo S 2014 Insulin signaling, resistance, and the metabolic syndrome: insights from mouse models to disease mechanisms. Journal of Endocrinology 220 T1-T23. (doi:10.1530/JOE-13-0327)
7. He L, Sabet A, Djedjos S, Miller R, Sun X, Hussain MA, Radovick S & Wondisford FE 2009 Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein. Cell 137 635-646. (doi:10.1016/j.cell.2009.03.016)
8. He L, Naik K,Meng S, Cao J, Sidhaye AR, Ma A, Radovick S & Wondisford FE 2012 Transcriptional co-activator p300 maintains basal hepatic gluconeogenesis. Journal of Biological Chemistry 287 32069-32077. (doi:10.1074/jbc.M112.385864)
9. He L, Cao J, Meng S, Ma A, Radovick S & Wondisford FE 2013 Activation of basal gluconeogenesis by co-activator p300 maintains hepatic glycogen storage. Molecular Endocrinology 27 1322-1332. (doi:10.1210/me.2012-1413)
10. Hundal RS, Petersen KF, Mayerson AB, Randhawa PS, Inzucchi S, Shoelson SE & Shulman GI 2002 Mechanism by which high-dose aspirin improves glucosemetabolismin type 2 diabetes. Journal of Clinical Investigation 109 1321-1326. (doi:10.1172/JCI0214955)
11. Landman GW, Kleefstra N, van Hateren KJ, Groenier KH, Gans RO & Bilo HJ 2010 Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care 33 322-326. (doi:10.2337/dc09-1380)
12. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD & Evans JM 2009 New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 32 1620-1625. (doi:10.2337/dc08-2175)
13. LiuY,DentinR,ChenD,Hedrick S,Ravnskjaer K, SchenkS,Milne J,MeyersDJ, Cole P, Yates J III et al. 2008 A fasting inducible switchmodulates gluconeogenesis via activator/coactivator exchange.Nature 456 269-273. (doi:10.1038/nature07349)
14. Nadeau KJ, Ehlers LB, Zeitler PS & Love-Osborne K 2009 Treatment of non-alcoholic fatty liver disease with metformin versus lifestyle intervention in insulin-resistant adolescents. Pediatric Diabetes 10 5-13. (doi:10.1111/j.1399-5448.2008.00450.x)
15. Roussel R, Travert F, Pasquet B, Wilson PW, Smith SC Jr, Goto S, Ravaud P, Marre M, Porath A, Bhatt DL et al. 2010 Metformin use and mortality among patients with diabetes and atherothrombosis. Archives of Internal Medicine 170 1892-1899. (doi:10.1001/archinternmed.2010.409)
16. Schwimmer JB, Behling C, Newbury R, Deutsch R, Nievergelt C, Schork NJ & Lavine JE 2005 Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology 42 641-649. (doi:10.1002/hep.20842)
17. Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, Depinho RA, Montminy M & Cantley LC 2005 The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310 1642-1646. (doi:10.1126/science.1120781)
18. Takashima M, Ogawa W, Hayashi K, Inoue H, Kinoshita S, Okamoto Y, Sakaue H, Wataoka Y, Emi A, Senga Y et al. 2010 Role of KLF15 in regulation of hepatic gluconeogenesis and metformin action. Diabetes 59 1608-1615. (doi:10.2337/db09-1679)
19. Wilcock C & Bailey CJ 1994 Accumulation of metformin by tissues of the normal and diabetic mouse. Xenobiotica 24 49-57. (doi:10.3109/00498259409043220)
20. Witters LA 2001 The blooming of the French lilac. Journal of Clinical Investigation 108 1105-1107. (doi:10.1172/JCI14178)
21. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N et al. 2001 Role of AMP-activated protein kinase in mechanism of metformin action. Journal of Clinical Investigation 108 1167-1174. (doi:10.1172/JCI13505)
22. Zhou XY, Shibusawa N, Naik K, Porras D, Temple K, Ou H, Kaihara K, Roe MW, Brady MJ & Wondisford FE 2004 Insulin regulation of hepatic gluconeogenesis through phosphorylation of CREB-binding protein. Nature Medicine 10 633-637. (doi:10.1038/nm1050)